163 related articles for article (PubMed ID: 23778908)
1. A historic moment for open science: the Yale University Open Data Access project and medtronic.
Krumholz HM; Ross JS; Gross CP; Emanuel EJ; Hodshon B; Ritchie JD; Low JB; Lehman R
Ann Intern Med; 2013 Jun; 158(12):910-1. PubMed ID: 23778908
[No Abstract] [Full Text] [Related]
2. Meta-analysis of trials of recombinant human bone morphogenetic protein-2: what should spine surgeons and their patients do with this information?
Resnick D; Bozic KJ
Ann Intern Med; 2013 Jun; 158(12):912-3. PubMed ID: 23778909
[No Abstract] [Full Text] [Related]
3. The changing structure of industry-sponsored clinical research: pioneering data sharing and transparency.
Kuntz RE
Ann Intern Med; 2013 Jun; 158(12):914-5. PubMed ID: 23778910
[No Abstract] [Full Text] [Related]
4. Closing in on the truth about recombinant human bone morphogenetic protein-2: evidence synthesis, data sharing, peer review, and reproducible research.
Laine C; Guallar E; Mulrow C; Taichman DB; Cornell JE; Cotton D; Griswold ME; Localio AR; Meibohm AR; Stack CB; Williams SV; Goodman SN
Ann Intern Med; 2013 Jun; 158(12):916-8. PubMed ID: 23778911
[No Abstract] [Full Text] [Related]
5. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis.
Fu R; Selph S; McDonagh M; Peterson K; Tiwari A; Chou R; Helfand M
Ann Intern Med; 2013 Jun; 158(12):890-902. PubMed ID: 23778906
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data.
Simmonds MC; Brown JV; Heirs MK; Higgins JP; Mannion RJ; Rodgers MA; Stewart LA
Ann Intern Med; 2013 Jun; 158(12):877-89. PubMed ID: 23778905
[TBL] [Abstract][Full Text] [Related]
7. YODA and truth seeking in medicine.
Doshi P; Vedula SS; Li T
BMJ; 2013 Jul; 347():f4251. PubMed ID: 23819966
[No Abstract] [Full Text] [Related]
8. Editorial: Recombinant human bone morphogenetic protein-2.
Shaffrey CI; Smith JS
J Neurosurg Spine; 2013 Feb; 18(2):109-10; discussion 110-1. PubMed ID: 23198758
[No Abstract] [Full Text] [Related]
9. Seroma observed 6 months after anterior lumbar interbody fusion that included use of recombinant bone morphogenetic protein 2.
Scheer JK; Dahdaleh NS; Smith ZA
Spine J; 2015 Oct; 15(10):e33. PubMed ID: 26022670
[No Abstract] [Full Text] [Related]
10. Retrograde ejaculation following single-level anterior lumbar surgery with or without recombinant human bone morphogenetic protein-2 in 5 randomized controlled trials: clinical article.
Burkus JK; Dryer RF; Peloza JH
J Neurosurg Spine; 2013 Feb; 18(2):112-21. PubMed ID: 23199378
[TBL] [Abstract][Full Text] [Related]
11. Medtronic submits full data on spinal protein to independent scrutiny.
Cohen D
BMJ; 2011 Aug; 343():d5484. PubMed ID: 21878463
[No Abstract] [Full Text] [Related]
12. Symptomatic heterotopic bone formation after rhBMP-2 utilization in lateral lumbar interbody fusion.
Aichmair A; Girardi FP; Hughes AP; Sama AA; Lebl DR; Cammisa FP
Spine J; 2013 Oct; 13(10):1411-2. PubMed ID: 24139750
[No Abstract] [Full Text] [Related]
13. Recombinant human bone morphogenetic protein-2-augmented transforaminal lumbar interbody fusion for the treatment of chronic low back pain secondary to the homogeneous diagnosis of discogenic pain syndrome: two-year outcomes.
Corenman DS; Gillard DM; Dornan GJ; Strauch EL
Spine (Phila Pa 1976); 2013 Sep; 38(20):E1269-77. PubMed ID: 23778368
[TBL] [Abstract][Full Text] [Related]
14. Blood serum antibody analysis and long-term follow-up of patients treated with recombinant human bone morphogenetic protein-2 in the lumbar spine.
Burkus JK; Gornet MF; Glassman SD; Slosar PJ; Rosner MK; Deckey JE; Nowak J; Hatcher BM
Spine (Phila Pa 1976); 2011 Dec; 36(25):2158-67. PubMed ID: 21325990
[TBL] [Abstract][Full Text] [Related]
15. A prospective, randomized, controlled trial comparing radiographic and clinical outcomes between stand-alone lateral interbody lumbar fusion with either silicate calcium phosphate or rh-BMP2.
Pimenta L; Marchi L; Oliveira L; Coutinho E; Amaral R
J Neurol Surg A Cent Eur Neurosurg; 2013 Nov; 74(6):343-50. PubMed ID: 23444134
[TBL] [Abstract][Full Text] [Related]
16. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 2: BMP dosage-related complications and long-term outcomes in 509 patients.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1137-45. PubMed ID: 23354111
[TBL] [Abstract][Full Text] [Related]
17. Folly of FDA-approval studies for bone morphogenetic protein.
Mirza SK
Spine J; 2011 Jun; 11(6):495-9. PubMed ID: 21729798
[No Abstract] [Full Text] [Related]
18. Exposing conflicts of interest and complications of rhBMP-2.
Chi JH
Neurosurgery; 2011 Oct; 69(4):N21-2. PubMed ID: 21900807
[No Abstract] [Full Text] [Related]
19. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 1: Large series diagnosis related outcomes and complications with 2- to 9-year follow-up.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1128-36. PubMed ID: 23370679
[TBL] [Abstract][Full Text] [Related]
20. Resetting standards for sponsored research: do conflicts influence results?
Spengler DM
Spine J; 2011 Jun; 11(6):492-4. PubMed ID: 21729797
[No Abstract] [Full Text] [Related]
[Next] [New Search]
